These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 17908970)

  • 1. The AA genotype of the regulatory BCL2 promoter polymorphism ( 938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients.
    Bachmann HS; Otterbach F; Callies R; Nückel H; Bau M; Schmid KW; Siffert W; Kimmig R
    Clin Cancer Res; 2007 Oct; 13(19):5790-7. PubMed ID: 17908970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The bcl2 -938CC genotype has poor prognosis and lower survival in renal cancer.
    Hirata H; Hinoda Y; Nakajima K; Kikuno N; Suehiro Y; Tabatabai ZL; Ishii N; Dahiya R
    J Urol; 2009 Aug; 182(2):721-7. PubMed ID: 19539330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.
    DeMichele A; Martin AM; Mick R; Gor P; Wray L; Klein-Cabral M; Athanasiadis G; Colligan T; Stadtmauer E; Weber B
    Cancer Res; 2003 Nov; 63(22):8051-6. PubMed ID: 14633738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases.
    Olopade OI; Adeyanju MO; Safa AR; Hagos F; Mick R; Thompson CB; Recant WM
    Cancer J Sci Am; 1997; 3(4):230-7. PubMed ID: 9263629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy.
    Yang Q; Sakurai T; Yoshimura G; Suzuma T; Umemura T; Nakamura M; Nakamura Y; Mori I; Kakudo K
    Oncol Rep; 2003; 10(1):121-5. PubMed ID: 12469156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic assessment of three single-nucleotide polymorphisms (GNB3 825C>T, BCL2-938C>A, MCL1-386C>G) in extrahepatic cholangiocarcinoma.
    Fingas CD; Katsounas A; Kahraman A; Siffert W; Jochum C; Gerken G; Nückel H; Canbay A
    Cancer Invest; 2010 Jun; 28(5):472-8. PubMed ID: 19968497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of chemotherapy on Ki-67, Bcl-2 and Bak expression in primary tumors and lymph node metastases of breast cancer.
    Koda M; Sulkowska M; Kanczuga-Koda L; Tomaszewski J; Kucharczuk W; Lesniewicz T; Cymek S; Sulkowski S
    Oncol Rep; 2007 Jul; 18(1):113-9. PubMed ID: 17549355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of glutathione S-transferase-pi in invasive breast cancer.
    Huang J; Tan PH; Thiyagarajan J; Bay BH
    Mod Pathol; 2003 Jun; 16(6):558-65. PubMed ID: 12808061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of the CC genotype of the regulatory BCL2 promoter polymorphism (-938C>A) with better 2-year survival in patients with glioblastoma multiforme.
    El Hindy N; Bachmann HS; Lambertz N; Adamzik M; Nückel H; Worm K; Zhu Y; Sure U; Siffert W; Sandalcioglu IE
    J Neurosurg; 2011 Jun; 114(6):1631-9. PubMed ID: 21250804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of Bcl-2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes.
    Arun B; Kilic G; Yen C; Foster B; Yardley D; Gaynor R; Ashfaq R
    Cancer; 2003 Dec; 98(12):2554-9. PubMed ID: 14669273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. bcl-2 and apoptosis in lymph node positive breast carcinoma.
    Berardo MD; Elledge RM; de Moor C; Clark GM; Osborne CK; Allred DC
    Cancer; 1998 Apr; 82(7):1296-302. PubMed ID: 9529021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Image cytometric bcl-2:bax and bcl-2:bcl-x ratios in invasive breast carcinoma: correlation with prognosis.
    Schiller AB; Clark WS; Cotsonis G; Lawson D; DeRose PB; Cohen C
    Cytometry; 2002 Aug; 50(4):203-9. PubMed ID: 12210599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression.
    Hughes S; Agbaje O; Bowen RL; Holliday DL; Shaw JA; Duffy S; Jones JL
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6673-80. PubMed ID: 18006768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma.
    Lehnerdt GF; Franz P; Bankfalvi A; Grehl S; Kelava A; Nückel H; Lang S; Schmid KW; Siffert W; Bachmann HS
    Ann Oncol; 2009 Jun; 20(6):1094-9. PubMed ID: 19196738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
    Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy.
    Hirata H; Hinoda Y; Kikuno N; Suehiro Y; Shahryari V; Ahmad AE; Tabatabai ZL; Igawa M; Dahiya R
    J Urol; 2009 Apr; 181(4):1907-12. PubMed ID: 19237173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphism (ALA16VAL) correlates with regional lymph node status in breast cancer.
    Bica CG; da Silva LL; Toscani NV; Zettler CG; Gottlieb MG; Alexandre CO; Graudenz MS; Mânica da Cruz IB
    Cancer Genet Cytogenet; 2010 Jan; 196(2):153-8. PubMed ID: 20082851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clusterin expression predicts survival of invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy.
    Watari H; Ohta Y; Hassan MK; Xiong Y; Tanaka S; Sakuragi N
    Gynecol Oncol; 2008 Mar; 108(3):527-32. PubMed ID: 18177691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of BCL2-938 C>A promoter polymorphism and BCL2 gene expression on the progression of breast cancer.
    Bhushann Meka P; Jarjapu S; Vishwakarma SK; Nanchari SR; Cingeetham A; Annamaneni S; Mukta S; Triveni B; Satti V
    Tumour Biol; 2016 May; 37(5):6905-12. PubMed ID: 26662799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
    Kröger N; Milde-Langosch K; Riethdorf S; Schmoor C; Schumacher M; Zander AR; Löning T
    Clin Cancer Res; 2006 Jan; 12(1):159-68. PubMed ID: 16397038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.